Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Anakinra (Primary)
- Indications Haemochromatosis; Rheumatic disorders
- Focus Therapeutic Use
- Acronyms THERA
- 03 Jul 2017 Planned End Date changed from 1 Jan 2018 to 1 May 2019.
- 03 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Feb 2019.
- 17 Feb 2015 According to ClinicalTrials.gove record the primary endpoint time frame has been changed from 90 days to 15 days.